On hold programs

Commercial name Active substance Indication
Xtandi® enzalutamide treatment of adult men with metastatic hormone‐sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (pending final marketing authorisation)
Last updated on 13/04/2021